Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 516

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

Open access
Marin, David, Li, Ye, Basar, Rafet, Rafei, Hind, Daher, May, Dou, Jinzhuang, Mohanty, Vakul, Dede, Merve, Nieto, Yago, Uprety, Nadima, Acharya, Sunil, Liu, Enli, Wilson, Jeffrey, Banerjee, Pinaki, Macapinlac, Homer A., Ganesh, Christina, Thall, Peter F., Bassett, Roland, Ammari, Mariam, Rao, Sheetal, Cao, Kai, Shanley, Mayra, Kaplan, Mecit, Hosing, Chitra, Kebriaei, Partow, Nastoupil, Loretta J., Flowers, Christopher R., Moseley, Sadie Mae, Lin, Paul, Ang, Sonny, Popat, Uday R., Qazilbash, Muzaffar H., Champlin, Richard E., Chen, Ken, Shpall, Elizabeth J., Rezvani, Katayoun·2024·Nature Medicine

Abstract

There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19+ B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR). Secondary objectives included day 100 response, progression-free survival, overall survival and CAR19/IL-15 NK cell persistence. No notable toxicities such as cytokine release syndrome, neurotoxicity or graft-versus-host disease were observed. The day 30 and day 100 OR rates were 48.6% for both. The 1-year overall survival and progression-free survival were 68% and 32%, respectively. Patients who achieved OR had higher levels and longer persistence of CAR-NK cells. Receiving CAR-NK cells from a cord blood unit (CBU) with nucleated red blood cells ≤ 8 × 10 7 and a collection-to-cryopreservation time ≤ 24 h was the most significant predictor for superior outcome. NK cells from these optimal CBUs were highly functional and enriched in effector-related genes. In contrast, NK cells from suboptimal CBUs had upregulation of inflammation, hypoxia and cellular stress programs. Finally, using multiple mouse models, we confirmed the superior antitumor activity of CAR/IL-15 NK cells from optimal CBUs in vivo. These findings uncover new features of CAR-NK cell biology and underscore the importance of donor selection for allogeneic cell therapies. ClinicalTrials.gov identifier: NCT03056339.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02785-8

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 516

Metadata

Authors
Marin, D., Li, Y., Basar, R., Rafei, H., Daher, M., Dou, J., Mohanty, V., Dede, M., Nieto, Y., Uprety, N., Acharya, S., Liu, E., Wilson, J., Banerjee, P., Macapinlac, H. A., Ganesh, C., Thall, P. F., Bassett, R., Ammari, M., Rao, S., Cao, K., Shanley, M., Kaplan, M., Hosing, C., Kebriaei, P., Nastoupil, L. J., Flowers, C. R., Moseley, S. M., Lin, P., Ang, S., Popat, U. R., Qazilbash, M. H., Champlin, R. E., Chen, K., Shpall, E. J., & Rezvani, K.
Venue
Nature Medicine
Published
2024-01-18
Volume
30
Issue
3
Pages
772-784
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4390975865
Cited by
516
References
74
FWCI
79.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. https://app.cochat.ai/papers/10.1038/s41591-023-02785-8
The paper
Marin, D., Li, Y., Basar, R., Rafei, H., Daher, M., Dou, J., Mohanty, V., Dede, M., Nieto, Y., Uprety, N., Acharya, S., Liu, E., Wilson, J., Banerjee, P., Macapinlac, H. A., Ganesh, C., Thall, P. F., Bassett, R., Ammari, M., . . . Rezvani, K. (2024). Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02785-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.